Letter: oral low-dose methotrexate for collagenous colitis

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 1, 2016, Pages 97-

  Kia, Y H ^a   Ting, A Y S ^a   Dowling, D ^a,b  

^a UNIVERSITY HOSPITAL GEELONG   (Australia)

^b DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

AGED; BLOOD TOXICITY; CLINICAL ARTICLE; COLLAGENOUS COLITIS; COLON BIOPSY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LETTER; LIVER TOXICITY; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY;

EID: 84977622419     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13638     Document Type: Letter

References (4)

1. Fernández-Bañares F, Casanova MJ, Arguedas Y, et al. Spanish Microscopic Colitis Group (SMCG). Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther 2016; 43: 400–26.
2. Riddell J, Hillman L, Chiragakis L, et al. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes. J Gastroenterol Hepatol 2007; 22: 1589–93.
3. Münch A, Bohr J, Vigren L, et al. Lack of effect of methotrexate in budesonide-refractory collagenous colitis. Clin Exp Gastroenterol 2013; 6: 149–52.
4. Hoekstra M, Van Ede AE, et al. Ann Rheum Dis 2003; 62: 423–6.